Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Reports Q2 revenue $7.1B, consensus $6.96B. Biktarvy sales increased 9% y/y to $3.5B. “This was a very successful second quarter for Gilead ...

Gilead Sciences (GILD) upgraded to Buy by Truist after raising its 2023 sales outlook. Read more here.

Gilead said its second-quarter cell therapy sales fell 7% to $485 million due to increased competition, while sales of cancer drug Trodelvy rose 14% to $364 million.

Gilead Sciences raised its guidance for the year after posting better-than-expected results in the second quarter, driven by higher sales from several drugs across its portfolio. The Foster City ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. The uptake of Trodelvy has been good.